Register for free to
view the full innovation profile.
Although preclinically evaluated as a cancer vaccine, with the proper soluble antigen this composition can potentially enhance response to other traditional vaccine targets.
About
Description Although traditionally viewed as an anti-infectious preventive measure, vaccine use has expanded to treating non-infectious diseases including cancer. Provenge (Dendreon) is currently the only FDA approved therapeutic vaccine at approximately $95,000 per treatment. Therapeutic vaccines in clinical trials are targeting glioblastoma, cervical, skin, head, neck, pancreatic, breast and lung cancer; as well as celiac disease and recurrent yeast infections from companies like GlaxoSmithkline, Rxi Pharmaceuticals and Pevion Vaccines. Advantages of the Invention The invention, a recombinant vaccine composition, combines the beneficial traits of Fc tagged subunit and DNA vaccine paradigms, coupled with Virus-like particle aggregate antigen delivery to produce a robust immune response and induction of CD4 and CD8 T cells. Although preclinically evaluated as a cancer vaccine, with the proper soluble antigen this composition can potentially enhance response to other traditional vaccine targets.